Esperion to Host Virtual Key Opinion Leader Event
In a significant move for the biopharmaceutical landscape, Esperion has announced it will host a virtual key opinion leader (KOL) event to delve into the pressing issues surrounding LDL-Cholesterol management and its implications for cardiovascular disease prevention. This announcement comes amid ongoing discussions about the unmet needs in this critical area of healthcare, ensuring that patients receive the best therapeutic options available.
Insights from Industry Leaders
The event is set to be led by LeAnne Bloedon, who serves as the Vice President and Head of Clinical Development at Esperion. She will engage in a compelling dialogue with distinguished expert Patrick Moriarty, M.D., who is a Professor of Medicine at The University of Kansas Medical Center and the Director of Clinical Pharmacology at the Atherosclerosis & Lipid-Apheresis Center. Their expertise promises to shed light on the real-world applications of `NEXLETOL (bempedoic acid)` and `NEXLIZET (bempedoic acid and ezetimibe)` as effective solutions for managing high cholesterol levels.
Registration and Accessibility
Individuals interested in participating can easily register for the KOL webinar through the official channels. In addition, a live audio webcast of the event will be available for access on Esperion's investor and media platform. This accessibility ensures that those unable to join in real time will still be able to engage with the content, as a replay will be archived on the company’s website for an extended period, allowing for flexibility for attendees.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is committed to addressing unmet patient needs through innovative biopharmaceutical solutions. Focused on developing medicines that tackle elevated low-density lipoprotein cholesterol (LDL-C), the company has made significant strides in providing FDA-approved, oral treatment options, thereby making a meaningful impact on patients at risk for cardiovascular diseases. Through pivotal trials, such as the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients, Esperion continues to affirm the efficacy and safety of its medications.
Future Directions and Innovations
Esperion is not stopping at existing products; it is actively cultivating its pipeline with next-generation programs aimed at advancing ATP citrate lyase inhibitors (ACLYi). These advancements are rooted in newly acquired insights into ACLYi's structure and functionality, presenting opportunities for rational drug design. Esperion aims to develop highly effective and targeted medications leveraging allosteric mechanisms, thereby enhancing treatment outcomes for patients struggling with high cholesterol.
Global Leadership and Partnerships
As Esperion Therapeutics, Inc. continues to establish itself within the global biopharmaceutical framework, it is fostering international collaborations and refining its operational strategies. The company's unyielding focus on commercial execution and expanding its clinical endeavors positions it as a leader in the cardiovascular treatment arena. Such developments are crucial as they not only enhance patient care but also contribute to the broader discourse on health and wellness in our society.
Esperion Contact Information
If you have questions or require further information, Esperion welcomes inquiries from both investors and media representatives. Investors can reach out to Alina Venezia via email at investorrelations@esperion.com or call (734) 887-3903. For media inquiries, Tiffany Aldrich is available at corporateteam@esperion.com or by phone at (616) 443-8438.
Frequently Asked Questions
What is the focus of the upcoming Esperion event?
The event will focus on LDL-Cholesterol management and the use of NEXLETOL and NEXLIZET in real-world scenarios.
Who are the featured speakers at the event?
The event will feature LeAnne Bloedon and Dr. Patrick Moriarty as key speakers.
How can I access the event?
Participants can register for the event online, and a live audio webcast will also be available.
What is Esperion's main goal?
Esperion aims to provide effective treatments for patients with high cholesterol to prevent cardiovascular diseases.
How can I contact Esperion for more information?
For inquiries, you can contact their investor relations or media representatives via email or phone.
